A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Stopped The Sponsor terminated the study because development of cibisatamab has been discontinued.

Conditions

• Colorectal Cancer

Interventions

• DRUG: Obinutuzumab
• DRUG: Atezolizumab
• DRUG: Cibisatamab
• DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche